CARB-X funds Contrafect to develop a new class of antibiotics to treat serious infections caused by Gram-negative ESKAPE Superbugs

CARB-X is awarding ContraFect Corporation (Nasdaq:CFRX) of Yonkers, New York, USA, up to $1.75 million in non-dilutive funding with the possibility of $5.19 million more if certain project milestones are met, to develop novel antibiotics to treat serious life-threatening infections caused by Gram-negative ESKAPE pathogens. This is ContraFect’s second antibacterial project to earn CARB-X funding.

Article: CARB-X

Smart Innovations  

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin